C360 Spine Portfolio Unveiled – NuVasive Advises Launch Represents a Significant Opportunity for Growth As Cervical Spine Procedures Comprise An Approximately $2.6 Bil Segment of the Global Spine Market

November 30, 2020

NuVasive has expanded its product line with the introduction of a new C360 cervical spine portfolio. The company has also commercially launched its new anterior cervical plating (ACP) system, which is claimed to feature the thinnest plate on the market at 1.6mm.

NuVasive has designed a new ACP system to minimize common postoperative complications such as dysphagia, malalignment, and adjacent level ossification.

The system helps surgeons to customize treatment as per customer requirements compared to the traditional one-size-fits-all approach.

Features of new anterior cervical plating system

The new ACP system features three plate profiles, including a thin-plate for one and two levels, and offers optimized plate stiffness for each surgical level to support construct stability.

NuVasive’s system offers a range of implant length options to match different patient anatomies and maximize the distance from the adjacent levels.

In addition, the system consists of a range of advanced screw offerings with integrated locking covers to facilitate better screw placement and locking accuracy.

The C360 portfolio also includes the Reline Cervical posterior fixation system, which is expected to be commercialized in 2021.

NuVasive executive vice president Massimo Calafiore said: “As the leader in spine technology innovation, NuVasive saw an opportunity to procedurally integrate technology to support the cervical spine—as it did in the lateral market with X360—to optimize the surgeon experience and advance care in the operating room.

“The launch of C360 is key to our long-term strategy and represents a significant opportunity for growth, as cervical spine procedures comprise an approximately $2.6 billion segment of the global spine market.”

NuVasive offers procedural solutions, including access, implants and fixation systems, biologics, software for surgical planning, and navigation and imaging solutions.

In November, NuVasive expanded its Porous PEEK portfolio with the commercial introduction of a new Cohere extreme lateral interbody fusion (XLIF) system.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.